CagriSema News: Latest Trial Results, Safety Data, and What Comes Next

CagriSema is an investigational once-weekly injection that combines cagrilintide and semaglutide, and the headline cagrisema news is that its phase 3 REDEFINE program produced roughly 22.7% average weight loss at 68 weeks in adults with obesity. That result beat semaglutide alone but landed below the 25% figure many analysts had expected. CagriSema is not approved by the FDA for any use, and Novo Nordisk has signaled it plans to file for regulatory review in the first quarter of 2026.

What Is CagriSema, Exactly?

CagriSema is a fixed-dose combination of two gut-hormone drugs, cagrilintide and semaglutide, given as a once-weekly subcutaneous injection. Cagrilintide is a long-acting amylin analog, while semaglutide is the GLP-1 receptor agonist sold as Ozempic and Wegovy. Because it targets two appetite pathways instead of one, researchers have watched it closely as a possible next step beyond single-hormone weight loss medications.

• Developer: Novo Nordisk
• Form: Once-weekly injectable pen
• Doses studied in phase 3: 2.4 mg cagrilintide plus 2.4 mg semaglutide
• Status: Investigational; not FDA-approved
• Lead trials: REDEFINE 1, REDEFINE 2, and REDEFINE 3

CagriSema is not legally available by prescription in the United States as of the latest available information.

REDEFINE 1 and REDEFINE 2: What the Trials Showed

REDEFINE 1 enrolled adults with obesity or overweight plus at least one weight-related condition, and none of the participants had type 2 diabetes. People were randomized to CagriSema, cagrilintide alone, semaglutide 2.4 mg alone, or placebo for 68 weeks, using a flexible dose-escalation schedule.

Treatment arm	Average weight loss at 68 weeks
CagriSema (cagrilintide + semaglutide)	About 22.7%
Cagrilintide 2.4 mg	About 11.8%
Semaglutide 2.4 mg (Wegovy dose)	About 16.1%
Placebo	About 2.3%

One detail drove most of the post-trial commentary: only about 57% of participants in the CagriSema arm reached the highest dose by week 68. Novo Nordisk later reported that people who did reach the full dose lost more weight on average, which is one reason the company kept refining dosing strategies instead of dropping the program.

REDEFINE 2 tested CagriSema in adults with type 2 diabetes plus overweight or obesity. Weight loss in that population was lower, roughly 13.7% on average, which fits the broader pattern that people with diabetes tend to lose less weight on GLP-1-based therapies.

How CagriSema Compares With Other Weight Loss Drugs

CagriSema is not the only option researchers are tracking, and the comparison below uses trial averages rather than head-to-head data. Cross-trial numbers are not directly interchangeable because populations, durations, and analyses differ.

Drug	Mechanism	Average weight loss in trials	Status
CagriSema	Amylin analog + GLP-1 agonist	About 22.7% at 68 weeks	Investigational
Semaglutide 2.4 mg (Wegovy)	GLP-1 agonist	About 15% at 68 weeks	FDA-approved for weight management
Tirzepatide (Zepbound)	GIP and GLP-1 dual agonist	About 21% at 72 weeks	FDA-approved for weight management
Retatrutide	GIP, GLP-1, and glucagon triple agonist	Up to about 24% in phase 2	Investigational

Eli Lilly's tirzepatide already competes directly with semaglutide in the US market, and retatrutide could raise the bar again if later trials hold up. CagriSema's commercial case therefore depends heavily on how its final label, tolerability, and pricing compare with drugs that are already on shelves.

Side Effects and Safety Signals

Gastrointestinal complaints were the most common side effects reported in the REDEFINE trials, consistent with the rest of this drug class. Most were mild to moderate and tended to fade as the body adjusted, though a portion of participants discontinued treatment because of them.

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Injection-site reactions

Rare but serious risks reported across GLP-1 and amylin-based drugs include pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas. Medications in this class also carry a boxed warning about thyroid C-cell tumors based on rodent studies, and they are not recommended during pregnancy.

Anyone weighing a GLP-1-based treatment should discuss personal risks, drug interactions, and monitoring with a licensed healthcare professional rather than relying on trial averages alone.

Dosage, Price, and Availability

There is no official cagrisema dosage chart yet, because the combination has not been approved by any regulator. In phase 3 trials, participants started low and escalated slowly toward a target of 2.4 mg cagrilintide plus 2.4 mg semaglutide once weekly, and the slow ramp is what most people failed to complete on schedule.

There is also no published cagrisema price. Novo Nordisk typically sets US list prices only after an approval decision, and insurance coverage, rebates, and savings programs usually change the real out-of-pocket number. For context, Wegovy and Zepbound currently list above $1,000 per month before discounts.

Searches for cagrisema where to buy mostly surface gray-market peptide vendors, overseas pharmacies, and social media sellers. Those products are unapproved, unregulated, and frequently mislabeled or contaminated. Anyone who follows research chemicals news has seen the same pattern with other unapproved peptides, where certificates of analysis are easy to fake and sterility cannot be verified from a website.

What to Watch Next in CagriSema News

Three developments are worth tracking over the next 12 to 24 months:

1. Regulatory filing. Novo Nordisk has indicated it intends to submit CagriSema for review, and the FDA's decision timeline will shape when, or whether, the drug reaches pharmacies.
2. REDEFINE 3 cardiovascular outcomes. That trial is testing whether the combination reduces major cardiovascular events in people with established heart disease, which matters for both labels and payer coverage.
3. Competition. Oral options such as oral semaglutide and orforglipron, plus Novo Nordisk's own amycretin, could change how much room CagriSema has in the market.

Bottom Line

CagriSema delivers the strongest weight loss numbers Novo Nordisk has reported in a phase 3 program, but it is still an investigational drug without FDA approval. The 22.7% average weight loss in REDEFINE 1 is meaningful, the dose-escalation challenges are real, and the safety profile resembles the rest of the GLP-1 class. Until regulators act, any product marketed online as CagriSema should be treated as unverified and potentially unsafe.

RELATED PEPTIDE TOPICSemaglutide research

COMMON QUESTIONS

Frequently Asked Questions

How much weight loss does CagriSema cause?

In the REDEFINE 1 trial, adults with obesity but without diabetes lost about 22.7% of their body weight on average over 68 weeks, compared with roughly 16.1% for semaglutide 2.4 mg and 2.3% for placebo. REDEFINE 2, which enrolled people with type 2 diabetes, showed about 13.7% average weight loss. Individual results vary based on dose reached, treatment duration, and personal health factors.

Is CagriSema FDA approved?

No. CagriSema is an investigational drug and has not been approved by the FDA for weight loss, diabetes, or any other indication. Novo Nordisk has signaled plans to file for regulatory review in the first quarter of 2026, but no approval decision has been made.

How is CagriSema different from Wegovy?

Wegovy contains semaglutide alone, which works through the GLP-1 receptor. CagriSema pairs semaglutide with cagrilintide, a long-acting amylin analog, so it targets a second appetite pathway. In trials, that combination produced greater average weight loss than semaglutide 2.4 mg alone.